International AIDS Vaccine Initiative & Mapp Biopharmaceutical
2 shared events · Importance 3 · Last updated May 30, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Tech
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing rVSV Bundibugyo, a single-dose vaccine candidate seen as promising by the World Health Organization, though it is not yet ready for trials.
Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.
May 28, 2026 · 6 articles
Accidents
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing a Bundibugyo-specific version of a vaccine using a platform similar to Merck & Co.'s Ervebo vaccine, contributing to the search for a treatment.
Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.
May 18, 2026 · 505 articles
NEWSDESK
Explore this relationship live
Track how International AIDS Vaccine Initiative and Mapp Biopharmaceutical interact across events, view sentiment trends, and discover connected entities.
Open Dashboard